Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 12/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | DRD2 | P14416 | 1/20 | 0.76 |
| ▸ | HTR7 | P34969 | 1/20 | 0.76 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14903760 | 1.00 | TAAR1 (0.76) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Hydrochloric Acid SCHEMBL28514686 | 0.98 | TAAR1 (0.74) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL20964274 | 0.87 | TAAR1 (0.66) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL14903737 | 0.86 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL12644523 | 0.86 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL14903727 | 0.86 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL21273312 | 0.85 | TAAR1 (0.97) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL21273308 | 0.85 | TAAR1 (0.97) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL21273309 | 0.85 | TAAR1 (0.97) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Ulotaront SCHEMBL28517004 | 0.85 | TAAR1 (0.97) | TAAR1HTR1ADRD2HTR7KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738002-B2 | Methods of treating neurological and psychiatric disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210315859-A1 | METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | SUMITOMO PHARMA AMERICA, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20200179336-A1 | METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2020-06-11 | — | — | US | disclosed |
| WO-2019161236-A1 | METHODS OF TREATING SOCIAL FUNCTION DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2507245-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | TAAR1 2272/4885HTR1A 394/4885DRD2 308/4885 |
| US-20200179336-A1 | METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRIN2A, SLC6A3, GRIN2C | TAAR1 131/4885HTR1A 27/4885DRD2 20/4885 |
| US-11738002-B2 | Methods of treating neurological and psychiatric disorders | GRIN2A, SLC6A3, GRIN2C | TAAR1 131/4885HTR1A 27/4885DRD2 20/4885 |
| US-20210315859-A1 | METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRIN2A, SLC6A3, GRIN2C | TAAR1 131/4885HTR1A 27/4885DRD2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.